Regeneron Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $3.12B | $2.49B | $2.73B | $3.11B | $2.89B | $2.19B | $1.62B | $1.47B |
| Accounts Receivable | $5.74B | $6.21B | $5.67B | $5.33B | $6.04B | $4.11B | $2.10B | $1.72B |
| Inventory | $3.20B | $3.09B | $2.58B | $2.40B | $1.95B | $1.92B | $1.42B | $1.15B |
| Total Current Assets | $18.02B | $18.66B | $19.48B | $15.88B | $14.01B | $9.78B | $7.69B | $6.45B |
| Property, Plant & Equipment | — | — | — | — | — | — | — | $2.58B |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | $1.26B | $1.15B | $1.04B | $915.5M | $6.7M | — | — | — |
| Total Assets | $40.56B | $37.76B | $33.08B | $29.21B | $25.43B | $17.16B | $14.81B | $11.73B |
| Liabilities | ||||||||
| Accounts Payable | $939.0M | $789.5M | $606.6M | $589.2M | $564.0M | $475.5M | $418.1M | $218.2M |
| Total Current Liabilities | $4.37B | $3.94B | $3.42B | $3.14B | $3.93B | $2.70B | $2.10B | $1.44B |
| Long-Term Debt | $1.99B | $1.98B | $1.98B | $1.98B | $1.98B | $1.98B | $0 | — |
| Total Liabilities | $9.30B | $8.41B | $7.11B | $6.55B | $6.67B | $6.14B | $3.72B | $2.98B |
| Stockholders' Equity | ||||||||
| Retained Earnings | $35.80B | $31.67B | $27.26B | $23.31B | $18.97B | $10.89B | $7.38B | $5.25B |
| Total Stockholders' Equity | $31.26B | $29.35B | $25.97B | $22.66B | $18.77B | $11.03B | $11.09B | $8.76B |